M&T Bank’s BridgeBio Pharma BBIO Stock Holding History

M&T Bank’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$728K	Buy	9,775 +2,766	+39%	+$194K	﹤0.01%	1040
2026 Q1	$521K	Buy	7,009 +5	+0.1%	+$362	﹤0.01%	1112
2025 Q4	$536K	Buy	+7,004	New	+$460K	﹤0.01%	1091
2021 Q1	–	Sell	-5,319	Closed	-$378K	–	1573
2020 Q4	$378K	Sell	5,319 -931	-15%	-$44.9K	﹤0.01%	1212
2020 Q3	$235K	Hold	6,250	–	–	﹤0.01%	1349
2020 Q2	$204K	Buy	+6,250	New	+$190K	﹤0.01%	1374
2020 Q1	–	Sell	-7,000	Closed	-$245K	–	1567
2019 Q4	$245K	Buy	+7,000	New	+$194K	﹤0.01%	1175

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

M&T Bank's BBIO Position: Q2 2026 in Review

M&T Bank increased its BridgeBio Pharma (BBIO) stake by 39% in Q2 2026, buying an estimated $194K and bringing the position to 9,775 shares worth $728K. The position accounts for ﹤0.01% of the portfolio, ranked #1040.

M&T Bank first reported a position in BBIO in Q4 2019 and has held it in 7 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

M&T Bank held 9,775 shares of BridgeBio Pharma worth $728K as of Q2 2026.
M&T Bank bought 2,766 BridgeBio Pharma shares in Q2 2026, an estimated $194K.
BridgeBio Pharma made up ﹤0.01% of M&T Bank's portfolio in Q2 2026, its #1040 holding.
M&T Bank first reported a position in BridgeBio Pharma in Q4 2019 and has held it in 7 quarters since.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.